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Bladder cancer accounts for approximately 8% and 6% of all new
male cancers and 4% and 3% of male cancer deaths each year in
the United Kingdom and the USA respectively (Silverman et al,
1999). Three quarters of all cases present as superficial disease and
whilst half of these cases are cured by simple treatment, about half
will develop recurrences (Gilbert et al, 1978). The field change
theory of recurrence proposes that each recurrence has arisen de
novo from a generalized precancerous urothelium (Raghavan et al,
1990; Harris and Neal, 1992). The clonal origin of recurrence
(Sidransky et al, 1992; Habuchi et al, 1993; Chern et al, 1996)
implies that either residual cells have been left at TURBT resulting
in tumour recurrence at the original site or that intraluminal shed-
ding and subsequent seeding occurs at the time of TURBT. There
are several reports supporting this shedding and seeding hypo-
thesis (Soloway and Masters, 1980; See et al, 1989; Rebel et al,
1994; Fadl-Elmula et al, 1999) and the effect of reduction in recur-
rence rate following intravesical instillation of various agents at
the time of TURBT supports this concept (Lamm and Griffith,
1992). There is a clear need for models in which to investigate the
process of bladder cancer seeding and invasion and also upon
which to test potential therapeutic agents. 
The most commonly used models of invasion are the Boyden
chamber and some form of matrigel assay. It is now clear that the
extracellular matrix is more than a passive support but interacts
with tumour cells regulating differentiation (Fujiyama et al, 1995;
Scriven et al, 1997), proliferation (Southgate et al, 1994; Booth 
et al, 1997) and tumour angiogenesis (Vladovski et al, 1997).
Likewise xenograft models are often technically difficult, with
moderate levels of reproducibility and are more difficult to
control. Therefore although these models have provided useful
information (Cook and Hampton, 1997; Miyake et al, 1997) they
are becoming inadequate. 
We have developed an in vitro model using de-epithelialized rat
bladder onto which human bladder cancer cells are seeded, an
analogous situation to seeding of cells at TURBT, and used this
model to test potential mechanisms and therapeutic inhibitors of
invasion. 
The plasminogen activator system regulates extracellular matrix
degradation and is therefore critical in tumour cell implantation,
invasion and metastasis (Conese and Blasi, 1995; Hudson and
McReynolds, 1997). The most common plasminogen activator,
urokinase plasminogen activator (uPA) functions via its receptor,
urokinase plasminogen activator receptor (uPAR). High expres-
sion of both uPA and uPAR has been found to be of prognostic
significance in a number of tumours including bladder (Hasui et al,
1994; Pedersen et al, 1994; Dickinson et al, 1995). Using this
model we have investigated the effects of uPAR antagonists,
suramin and N-acetylcysteine. The latter two are compounds that
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modify tumour cell–extracellular matrix interactions and therefore
have clinical potential. 
Suramin is a potent antagonist of the binding of angiogenic
factors to their receptors (Pesenti et al, 1992) and an antagonist of
uPAR (Behrendt et al, 1993). It has shown anti-tumour activity in
prostate cancer, when given systemically, but a narrow therapeutic
window resulted in dose-limiting toxic side effects (Eisenberger 
et al, 1993). There is potential for suramin used intravesically
because there should be only limited systemic absorption due to its
large molecular weight. Therefore high intravesical concentrations
may be achievable (Walther et al, 1996). Not only have anti-
angiogenic strategies resulted in reduced tumour growth and 
vascularity in xenografts (Kim et al, 1993; O’Reilly et al, 1997;
Borgstrom et al, 1998) but interference with angiogenesis has also
reduced tumour cell invasion (Brooks et al, 1995; Skobe et al, 1997). 
The thiol N-acetylcysteine (NAC), interferes with tumour-cell
invasion and metastasis, probably due to inhibition of matrix
metalloproteinases (Albini et al, 1995). Furthermore NAC is an
inhibitor of the Ras oncogene (Irani et al, 1997), demonstrated by
transfection experiments, to be important in bladder cancer inva-
sion (Theodorescu et al, 1990). The EJ cell line has a mutated Ha-
Ras oncogene (Parada et al, 1982) and therefore we also tested the
ability of NAC to inhibit invasion in our model. 
Here we report the development and use of a rat bladder in vitro
model of bladder cancer invasion, which allows for extracellular
matrix interactions. Using this model the therapeutic potential of a
range of compounds is illustrated. Based on these findings, and
other observations (Pesenti et al, 1992; Behrendt et al, 1993;
Eisenberger et al, 1993; Walther et al, 1996), we have started a
phase I trial of intravesical suramin in patients with bladder cancer. 
MATERIALS AND METHODS 
Primary culture 
The established human transitional cell carcinoma (TCC) cell lines
used in this study were RT4, RT112, 253J and EJ28 (gift from 
Dr M Knowles, Imperial Cancer Research Fund, Leeds, UK).
These TCC cell lines display phenotypes associated with well-
differentiated, moderately differentiated, and anaplastic, poorly
differentiated TCC cells, respectively. Cell lines of truly super-
ficial bladder cancer do not exist. RT4 and RT112, although origi-
nally from invasive bladder cancers, behave in a superficial pattern
and are widely used as models of superficial bladder cancer
(Theodorescu et al, 1990; Redwood et al, 1992; Booth et al, 1997;
Davies et al, 1999), 253J and EJ28 are widely used as models of
invasive bladder cancer (Elliot et al, 1974; Redwood et al, 1992;
Theodorescu et al, 1998; Davies et al, 1999). 
Cell lines were cultured in a RPMI (Clare Hall laboratories,
Imperial Cancer Research Fund) supplemented with 10% fetal
bovine serum (FBS), penicillin G (45 mg ml–1), streptomycin
(45 mg ml–1), and kanamycin (90 mg ml–1), at 37˚C in a 5% CO2
humidified atmosphere. 
Doubling time of human bladder cancer cell lines 
To examine doubling time of these human bladder cancer cell
lines, 5 ´ 104 cells of each cell line were seeded in 6 well plates,
and the number of cells in each cell line were counted in triplicate
daily over the next 7 days. Doubling time of each cell line was
calculated during the exponential growth phase. 
In vitro invasion assay 
6-month-old Sprague-Dawley rats that had served as negative
controls in other experiments were used for these experiments.
The urinary bladder was removed through a laparotomy incision
and transferred to a universal container with sterile culture
medium for washing. Bladders were then cut into halves and
digested with a 1000 units ml–1 bacterial neutral protease (Dispase
I, Godo-Shusei Co Ltd, Tokyo, Japan) for 2 hours at room temper-
ature. The urothelium was then stripped off with dissecting forceps
and the hemibladders were then placed (de-epithelialized surface
face up) onto filter paper. The remaining stroma, with intact base-
ment membrane was then divided further to yield typically 3
sections (approximately 0.5 ´ 0.5 cm) from each hemibladder
(Figure 1). Typically experiments were performed using 6–8 rat
bladders. All explants were then pooled so that when each experi-
mental condition was performed in triplicate, each explant was
likely to originate from different bladders. Whilst this would
increase interindividual variation it was felt that such randomiza-
tion would minimize spurious effects from any one bladder. 
Three 30 mm diameter culture inserts (with a 0.4 mm pore size
nitrocellulose base – Millicell CM, Millipore, Bedford, MA) were
placed into a 10 cm culture dish. Onto each culture insert, 0.5 ml
of a collagen gel solution was pipetted (1 volume of 10 ´ concen-
tration RPMI [without NaHCO3], 1 volume of reconstruction
buffer [2.2 g NaHCO3 and 4.77 g HEPES in 100 ml 0.05 M
NaOH] and 8 volumes of type I collagen solution [Cellmatrix,
Nitta Gelatin Co Ltd, Osaka, Japan]). The bladder explants were
then removed from the filter paper and placed, de-epithelialized
surface uppermost, on the gel (up to 6 explant per insert). This was
then placed in the incubator at 37˚C for 15–30 minutes to fix the
de-epithelialized stroma on the gel. 
After 15–30 minutes, cultured cells to be applied were harvested
in the standard way with the exception that trypsin was neutralized
by mixing with 100% FBS and centrifuging (a process repeated
twice) to ensure that no traces of trypsin remained. Cells were then
resuspended in medium and the required number (1 ´ 105 RT112,
253J, EJ28 and 1 ´ 106 RT4, depending on cell line) was pipetted
in 2 ml of complete medium into each 30 mm culture insert. 6 ml
of complete medium were then placed in the 10 cm culture dish
outside the three 30 mm culture inserts. This protocol (6 ml
medium outside three 30 mm culture inserts) was the exact amount
of medium to create an air–liquid interface within each culture
insert at the level of the explant, which appears essential for
correct functioning of the assay. At 24 hours the 2 ml of medium in
the 30 mm culture insert was aspirated and not replaced. The
medium in the 10 cm culture dish was renewed every 3–4 days,
periods longer than this were associated with dehydration of the
explants. 
Assessment of invasion 
Organ cultures were harvested at 3, 7, 14 and 28 days. Each
explant was individually cut out of the insert, fixed in 10% neutral-
ized formalin and embedded in paraffin wax, with triplicates
embedded within the same block. Results represent one set of
histopathological sections taken from each explant, sectioned near
its centre, not multiple sections from different sites within the
same explant. Thus repeats are true repeats, representing results
from different explants, not just different histopathological
sections within the same explant. Histopathological sections (5 mm) were dewaxed and rehydrated through graded alcohols to
water. For histological evaluation, sections were stained and
examined as H and E sections. To quantify invasion, sections
were viewed at high power (´ 400) under a microscope. A 100,
1 mm ´ 1 mm, square graticule (Graticules Ltd, Tonbridge, UK)
was placed with the top edge along the upper surface of the explant
at the left hand edge of the section. To exclude false invasion
results due to an undulating upper surface of the rat explant and to
account for variable thicknesses of the stratified epithelium, which
did not represent invasion, the first 2 rows were not counted.
Thereafter all cells were counted in 2 mm deep rows, starting from
a depth of 2 mm to 10 mm. The whole section was counted by
moving the graticule from left to right. Results for each depth on
each section represent the average of at least 10 graticule counts.
Results illustrated graphically for each cell line/condition are the
means of 4–6 representative rat explants at each depth. Experi-
ments were repeated at least 3 times. 
Immunohistochemical staining 
The immunoreactivity of antigens masked by the tissue processing
was restored by 10 minutes of digestion in 0.1% trypsin and
microwave boiling. Immunolabelling was performed using an
indirect streptavidin ‘ABC’ immunoperoxidase method (Dako,
High Wycombe, Bucks, UK). Non-specific background staining
was blocked by incubation in 10% swine serum. Sections were
incubated in primary antibody, against cytokeratin 18 (LP34,
Dako), Ki-67 (MIB-1, Beckman Coulter, High Wycombe, Bucks,
UK), and laminin (Sigma-Aldrich, Poole, Dorset, UK) and then
incubated with a biotin-labelled goat anti-mouse secondary anti-
body followed by horseradish peroxidase-conjugated streptavidin
ABC complex. The peroxidase reaction was developed using
diaminobenzidine and slides were washed and mounted in
aqueous mountant (Gurr, BDH Lab, Poole, Dorset, UK). 
Addition of inhibitors 
N-acetylcysteine (Sigma-Aldrich, Poole, Dorset, England), Å5 a
urokinase receptor antagonist (Ångstrom, San Diego, CA, gift of
Dr T Jones) and Mab 3936 an inhibitory antibody against urokin-
ase (American Diagnostica, Greenwich, CT) (Hudson and
McReynolds, 1997) were assessed for their ability to inhibit inva-
sion. To examine the direct effect of these reagents on the growth
of EJ28 cells in monolayer culture, 3 ´ 103 cells were seeded onto
a 96-well culture plate in 100 ml of conditioned medium with 10%
FBS. At 24 hours (day 1) the medium was changed to conditioned
medium containing inhibitor at multiple increasing concentrations
(from 0–1 mM for N-acetylcysteine and suramin, from 0–5 mM
for Å5 and from 0–20 mg ml–1 for Mab 3936). On day 4, cell
viability was measured using an MTT assay kit (Chemicon
International, Temecula, CA) according to the manufacturer’s
instructions and confirmed by examination under microscope. 
Following the results of these MTT assays, the concentrations
of these inhibitors to be tested in the in vitro assay were chosen as
1 mM for NAC and suramin and 5 mM for Å5 and 20 mg ml–1 for
Mab 3936. These concentrations were chosen because they were
non-toxic to our cells in the MTT assay and were able to be well
tolerated clinically when given either intravesically (suramin)
(Walther et al, 1996) or systemically at much higher concentration
(140 mg kg–1 body weight – approximately 0.9 mM kg–1) for 
the treatment of paracetomol (acetaminophen) overdose (N-
acetylcysteine) (Yip et al, 1998). These inhibitors were added in
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Figure 1 Experimental procedures of in vitro invasion assay. The left side of the figure demonstrates de-epithelialization of rat bladder. The centre of the figure
shows setting up the rat stroma on culture inserts. Human bladder cancer cells are seeded onto this de-epithelialized rat stroma. The right side demonstrates
the assessment of invasion. All cells are counted in 2 mm deep rows, starting from a depth of 2 mm, up to 10 mm (RT = room temperature, H and E =
haematoxylin and eosin). The grid for quantifying depth of invasion is shown schematically at the bottom right of the figure. In this example there would be 26
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0.1 ml of conditioned medium onto the surface of rat explants
from culture day 0 and thereafter every 24 hours. Control bladder
explants had medium only added. Separate petri dishes were used
for each control or inhibitor group to avoid cross-contamination in
the medium. 
Statistical analysis 
Statistical analysis was performed using Excel (Microsoft, CA).
Comparisons between groups were made using Student’s unpaired
t-test. 
RESULTS 
Growth characteristics of cell lines in vitro on
monolayer culture 
The 2 superficial cell lines, RT4 and RT112 both had similar but
slower mean (± S.D) doubling times than the 2 invasive cell lines,
253J and EJ28, which were similar to each other (RT4 56 h ± 3,
RT112 59 h ± 2 Vs 253J 31 h ± 1, EJ28 32 h ± 1, P = < 0.01, n = 3,
experiment repeated 3 times). 
Growth characteristics in the in vitro invasion 
model 
Organ cultures of rat de-epithelialized stroma have produced
reproducible results and could be kept viable for more than 28
days, although typically there was little change between 14 and 28
days. The 2 superficial cell lines reproducibly grew in a superficial
fashion, forming a stratified epithelium. This pattern was progres-
sive with time (Figure 2A–C RT4, D-F RT112) and no invasion
was seen although occasionally (about once in every 10 sections) a
‘nest’ of cells was seen within vessels in the stroma in RT112
cultures (Figure 2F). Whilst interesting, this is probably not
frequent enough to provide a model for vascular invasion. 
The 2 invasive lines showed disparate behaviour. 253J formed
superficial cell layers and did not invade (Figure 2J) whereas EJ28
invaded diffusely across a broad front. This invasion started as
early as 3 days (Figure 2G) and increased with time (Figure 2G–I).
In control de-epithelialized bladder explants, i.e. those not
reseeded with human bladder cancer cells, there was negligible
regrowth of normal rat urothelium (Figure 2I). 
Quantification of invasion 
Figure 3 quantifies the depth of invasion according to our method.
The number of cells counted in the stroma in control de-epithelial-
ized bladder explant sections and RT112 sections represents back-
ground levels for staining of normal stromal cells, such as
fibroblasts and smooth muscle cells. These are evenly distributed
throughout the stroma. The results for EJ28 include these back-
ground cells, but the higher counts are due to invading bladder
cancer cells, hence the decrease in number the further away from
the upper surface of the bladder. This was confirmed by staining
with the specific epithelial marker cytokeratin 18 (data not shown). 
Proliferation of cancer cell lines in vitro model 
As demonstrated, the doubling times for 253J and EJ28 were
similar in conventional monolayer culture. However, invasion in
our in vitro model is unlikely to be simply a manifestation of a
faster proliferation rate, since 253J did not invade into the stroma
whereas EJ28 did. Furthermore, in the invasion model RT112 and
EJ28 had similar proliferation rates as evidenced by Ki-67
immunostaining (data not shown). 
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Figure 2 Time course for growth on in vitro model for superficial tumour cell
lines RT4 and RT112 (A–F) and invasive tumour cell lines 253J and EJ28
(G–J). Both RT4 and RT112 formed stratified epithelium without invasion on
the de-epithelialized rat bladder mucosa. RT112 also very occasionally
formed a ‘nest’ of cells, seen in the stroma (F). 253J did not invade, but
formed a stratified epithelium (J), whereas EJ28 invaded diffusely into rat
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bladder tissue prior to any experimental procedure. L shows de-epithelialized
cultured rat bladder used as control. Results show representative histological
sections from experiment repeated ³5 times with ³3 bladder explants per
timepoint. Scale bar: 20 mm. Original magnification ´ 400. Inset, scale bar:
100 mm. Original magnification ´ 100 
120
100
80
60
40
20
0
EJ28
Rt112
Rat tissue
2 – 4 mm 4 – 6 mm 6 – 8 mm 8 – 10 mm
Depth of Stroma
C
e
l
l
 
c
o
u
n
t
s
 
(
c
e
l
l
s
/
2
0
m
m
2
)
Figure 3 Quantification of invasion. The number of cells counted in the
stroma of control stripped rat tissue and RT112 represent background levels
for normal cells, such as fibroblasts and smooth muscle cells. The results for
EJ28 includes these background cells, but the higher counts are due to
invading bladder cancer cells. Results illustrated from representative
experiment (day 14) are means ± S.D. of 10 graticule counts per histological
section, 6 explants per cell line. Experiment repeated 3 times. (As RT4 and
RT112 were both non-invasive, only 1 cell line was counted, but qualitatively
they were the same) The basement membrane for control rat bladder tissue and
RT112 sections showed positive staining with laminin but there
was no positive staining in EJ28 sections indicating degradation of
the basement membrane. 
Inhibition of invasion 
The MTT assay (n = 8 per concentration, experiment repeated
twice) showed no growth inhibition of N-acetylcysteine and
suramin on EJ28 cells up to 1 mM for 4 days and no inhibition by
Å5 up to 5 mM or by Mab 3936 up to 20 mg ml–1. However in the
in vitro invasion assay the invasion of EJ28 cells into the rat
stroma was significantly inhibited by suramin and N-acetyl-
cysteine (P < 0.05). Suramin had the greatest effect with almost
complete inhibition of invasion by EJ28 cells (Figure 4), whilst,
the least inhibition was seen with N-acetylcysteine (Figure 4). 
Inhibition of components of the plasminogen activator
system 
Inhibition of the plasminogen activator system blocked EJ28 inva-
sion effectively with Å5 and Mab 3936 producing inhibition
equivalent to each other and to suramin (P = 0.05 to 0.01 versus
control, but not significantly different from each other, unpaired 
t test). 
DISCUSSION 
Our model, using de-epithelialized rat bladder to expose the under-
lying stroma allows for these tumour cell–extracellular matrix
interactions and more direct analysis of new drugs or biochemical
mechanisms. We studied 4 cell lines that demonstrate phenotypes
associated with well, moderate and poorly differentiated TCC
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Figure 4 Inhibition of invasion of EJ28 cells in the in vitro model. (A),
control untreated EJ28 cells show characteristic invasion. N-acetylcysteine
(B) and suramin (C) inhibited the invasion of EJ28 cells into the rat stroma
within 7 days. (D) Quantification of invasion. N-acetylcysteine produced the
least, although still significant, reduction in invasion. Suramin caused the
greatest inhibition of invasion of EJ28 into the rat stroma with uPAR antibody
and Å5 intermediate. Results illustrated from representative experiment are
means ± S.D. of 10 graticule counts per histological section, 4–6 explants per
inhibitor. Experiment repeated 3 times. Scale bar: 20 mm. Original
magnification ´ 400. Inset, scale bar: 100 mm. Original magnification ´ 100.
(*P = 0.057, all other depths for all other inhibitors P = <0.05 vs EJ at that
level). 
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cells. RT4 and RT112 have been used as models of superficial non-
invasive tumours and 253J and EJ28 are models of invasive
bladder cancer (Elliot et al, 1974; Theodorescu et al, 1990;
Redwood et al, 1992; Booth et al, 1997; Theodorescu et al, 1998;
Davies et al, 1999). Although reported as invasive, 253J was not
invasive in our model. This probably confirms the importance of
multiple interactions for invasion to take place, one or more of
which were missing for 253J to invade. In our model since EJ28
invaded, the cell line was used to investigate the effects of various
inhibitors. 
Urokinase plasminogen activator (uPA) and urokinase plas-
minogen activator receptor (uPAR) correlated with invasion into
matrigel by bladder tumour cell lines in a previous study (Hudson
and McReynolds, 1997). Our study differed in that we studied a
complex stroma with viable cells, connective tissue, blood vessels
and analysed other mechanisms for modifying uPA effects. The
inhibition in our model with Mab 3936 confirmed the importance
of the plasminogen activator system in a realistic model of bladder
cancer invasion and pinpoints a potential therapeutic target
(Ossowki et al, 1991). We also tested Å5, a small cyclic peptide
inhibitor of uPAR, and found it was also able to block invasion.
This shows that uPA must associate with its cell surface receptor
for bladder tissue invasion and secretion is insufficient. Such strate-
gies may be useful after TURBT to prevent displaced cells seeding. 
A concentration of 1 mM suramin was able to completely
inhibit invasion. This level cannot be achieved systemically, but in
a phase 1 trial, it was found possible to achieve this level safely by
intravesical instillation. Thus further evaluation is justified. 
Booth et al have previously reported an in vitro model using
human urinary bladder (Booth et al, 1997). The latter is an excel-
lent model and human tissue obviously has advantages over rat
tissue when investigating human bladder cancer invasion,
although our model also has specific advantages. Firstly, it is
harder to maintain a regular supply of human bladder for experi-
ments. Secondly, the viability of these models depends on diffu-
sion of culture medium and the maintenance of an air–liquid
interface. This is relatively straightforward in the thinner rat
bladder, which can be kept viable for more than 28 days. Human
bladder cancer cell lines remain viable on rat de-epithelialized
stroma, because there is no immunological rejection in vitro.
Marked invasion into the rat stroma occurs within a short time,
7–14 days. This shorter experimental time, ease of handling and
plentiful supply means that this model will aid the investigation of
the mechanism of invasion and the testing of therapeutic agents.
This would become important if larger studies were to be done, for
example, investigating reversibility of effect with intermittent
treatment similar to weekly intravesical instillations. 
In conclusion, this study illustrates a reproducible and realistic
model of bladder cancer invasion. It has enabled a target concen-
tration of suramin for a phase I trial to be determined. It allows for
the study of the mechanisms involved in invasion. These processes
and the contribution of the stroma could be further elucidated by
using bladders from transgenic animals deficient in specific
components of the extracellular matrix. 
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